Home
Archives
Jerusalem Center Homepage
View the current issue
Jerusalem Center Videos
Additional Resources
Top Commentators:
- Elliott Abrams
- Fouad Ajami
- Shlomo Avineri
- Benny Avni
- Alan Dershowitz
- Jackson Diehl
- Dore Gold
- Daniel Gordis
- Tom Gross
- Jonathan Halevy
- David Ignatius
- Pinchas Inbari
- Jeff Jacoby
- Efraim Karsh
- Mordechai Kedar
- Charles Krauthammer
- Emily Landau
- David Makovsky
- Aaron David Miller
- Benny Morris
- Jacques Neriah
- Marty Peretz
- Melanie Phillips
- Daniel Pipes
- Harold Rhode
- Gary Rosenblatt
- Jennifer Rubin
- David Schenkar
- Shimon Shapira
- Jonathan Spyer
- Gerald Steinberg
- Bret Stephens
- Amir Taheri
- Josh Teitelbaum
- Khaled Abu Toameh
- Jonathan Tobin
- Michael Totten
- Michael Young
- Mort Zuckerman
Think Tanks:
- American Enterprise Institute
- Brookings Institution
- Center for Security Policy
- Council on Foreign Relations
- Heritage Foundation
- Hudson Institute
- Institute for Contemporary Affairs
- Institute for Counter-Terrorism
- Institute for Global Jewish Affairs
- Institute for National Security Studies
- Institute for Science and Intl. Security
- Intelligence and Terrorism Information Center
- Investigative Project
- Jerusalem Center for Public Affairs
- RAND Corporation
- Saban Center for Middle East Policy
- Shalem Center
- Washington Institute for Near East Policy
Media:
- CAMERA
- Daily Alert
- Jewish Political Studies Review
- MEMRI
- NGO Monitor
- Palestinian Media Watch
- The Israel Project
- YouTube
Government:
Back
(Israel21c) Abigail Klein Leichman - Based on a just-completed study involving 131 patients, Israel's Neuronix medical device company will apply for U.S. FDA approval for its neuroAD system to slow and even reverse the progression of Alzheimer's. The novel technology combines transcranial magnetic stimulation (TMS) and cognitive training of specific brain regions to slow the rate of mental deterioration in patients with mild to moderate Alzheimer's and other neurodegenerative disorders. The treatment is commercially available in Europe and Asia, including in Israel. Neuronix CEO Eyal Baror said, "Our previous successful six clinical trials have shown that neuroAD is safe and effective in treatment of mild to moderate Alzheimer patients, significantly improving their cognitive performance and day-to-day activities, and slowing down their mental deterioration for about one year." In 2015, Korean researchers said a clinical trial showed that neuroAD "was remarkable in the memory and language domains, which are severely affected by Alzheimer's disease." 2016-02-19 00:00:00Full Article
Israeli Device Slows Progression of Alzheimer's
(Israel21c) Abigail Klein Leichman - Based on a just-completed study involving 131 patients, Israel's Neuronix medical device company will apply for U.S. FDA approval for its neuroAD system to slow and even reverse the progression of Alzheimer's. The novel technology combines transcranial magnetic stimulation (TMS) and cognitive training of specific brain regions to slow the rate of mental deterioration in patients with mild to moderate Alzheimer's and other neurodegenerative disorders. The treatment is commercially available in Europe and Asia, including in Israel. Neuronix CEO Eyal Baror said, "Our previous successful six clinical trials have shown that neuroAD is safe and effective in treatment of mild to moderate Alzheimer patients, significantly improving their cognitive performance and day-to-day activities, and slowing down their mental deterioration for about one year." In 2015, Korean researchers said a clinical trial showed that neuroAD "was remarkable in the memory and language domains, which are severely affected by Alzheimer's disease." 2016-02-19 00:00:00Full Article
Search Daily Alert
|
Search:
|